ECM22 Antibody

What is CD22 and where is it primarily expressed in human tissue?

CD22 is a B cell-specific protein that serves as an important target for antibody therapy in various conditions. It is predominantly expressed on B cells and B cell malignancies. CD22 is found in B-cell acute lymphoblastic leukemia (B-ALL), with 50%-100% of adult B-ALL and approximately 90% of pediatric B-ALL malignant cells expressing this marker . Additionally, CD22 expression extends to other B cell malignancies including mantle cell lymphoma, follicular lymphoma, and diffuse large B cell lymphoma (DLBCL) . The protein consists of seven immunoglobular domains forming a large, rigid, heavily glycosylated ectodomain, which presents specific challenges for therapeutic targeting . Understanding this expression pattern is fundamental for researchers designing antibody-based interventions targeting B cell pathologies.

How does CD22 receptor density compare with other B cell surface markers?

CD22 receptor density presents a significant challenge for researchers due to its relatively modest expression levels. Studies have quantified CD22 density at approximately 2,839-3,470 molecules per cell , which is significantly lower (approximately 10-fold less) than CD19 . This lower density becomes even more pronounced after CAR targeting, as receptor expression can be further decreased following antibody therapy . When designing experiments, researchers should account for this differential expression by using appropriate sensitivity measures and controls. Quantification methods typically employ flow cytometry with specific antibodies such as anti-CD22-PE (clone S-HCL-1) alongside comparative markers like anti-CD19-PE and anti-CD20-PE to establish relative densities . This comparative approach allows for accurate assessment of target availability across different B cell populations.

What methodological approaches are recommended for measuring CD22 expression on clinical samples?

For accurate CD22 expression measurement in clinical samples, researchers should follow a systematic protocol. Begin by isolating mononuclear cells through Ficoll-Hypaque purification from blood samples collected in heparinized tubes . For immunostaining, block one million cells per sample with 2% FBS + 1% human serum in PBS (containing 0.05% sodium azide) for 20 minutes on ice to prevent non-specific binding . Apply 1 μg of anti-CD22-PE (clone S-HCL-1) alongside appropriate isotype controls and incubate for 30 minutes at 4°C protected from light . Following incubation, wash samples with 2 ml of HBSS and centrifuge at 500×g . For monitoring CD22 expression during clinical trials, non-competing anti-CD22 antibodies like S-HCL-1 can be used to avoid interference with therapeutic antibodies such as epratuzumab . Flow cytometry analysis should include appropriate gating strategies to distinguish different B cell subsets (naïve, memory, transitional) based on additional markers such as CD19, CD27, and IgD .

How can researchers optimize CD22 antibody internalization studies?

To effectively study CD22 antibody internalization kinetics, researchers should implement a time-course experimental design that accounts for different cell populations. Internalization rates should be measured indirectly using monovalently labeled, non-competing anti-CD22 antibodies, particularly when studying therapeutic antibodies like epratuzumab . The experimental protocol should compare internalization rates across multiple cell types, including established B cell lines, primary B cells from healthy donors, and patient-derived samples . It's critical to note that internalization kinetics differ significantly between cell lines and primary B cells, with cell lines typically showing faster early internalization . For accurate quantification, include multiple time points (early time points are particularly important) and antibody concentration gradients (1-5 μg/ml appears to reach saturation for most systems) . Temperature controls are essential, as internalization mechanisms are temperature-dependent. Complementary approaches such as confocal microscopy can provide visual confirmation of internalization events to strengthen quantitative data.

What are the challenges and solutions in developing dual-targeting approaches for CD19 and CD22?

Developing effective dual-targeting strategies for CD19 and CD22 presents several technical challenges that require systematic research approaches. The primary challenge lies in the approximately 10-fold difference in expression density between CD19 and CD22, which can lead to preferential targeting of the more abundant CD19 receptor . Additionally, CD22's large, rigid ectodomain can impede immune synapse formation, compromising CAR function .

To address these challenges, researchers should consider:

• Testing multiple distinct antibody candidates (a panel of at least 10-12 different antibodies) targeting different epitopes within immunoglobular domains 3-6 of CD22

• Evaluating sensitivity to low CD22 density through titration experiments

• Assessing tonic signaling characteristics of potential CARs

• Exploring optimal co-targeting strategies beyond simple co-administration, which can be prohibitively expensive

Research shows that affinity and membrane proximity of the recognition epitope within CD22 do not necessarily correlate with CAR function, suggesting that empirical testing remains essential . When designing experiments, researchers should systematically evaluate both single CARs with dual specificity and co-administration approaches, measuring outcomes in models that recapitulate the clinical challenge of antigen escape.

What signaling effects does CD22 antibody binding induce in B cells?

CD22 antibody binding induces significant intracellular signaling events that researchers should measure through specific biochemical approaches. When epratuzumab binds to CD22, it triggers CD22 phosphorylation, which can be quantified via immunoprecipitation followed by Western blot analysis . These phosphorylation events should be compared with those induced by anti-IgM stimulation to contextualize their physiological relevance . Beyond direct CD22 phosphorylation, researchers investigating signaling mechanisms should examine downstream effects on B Cell Receptor (BCR)-related proteins, as epratuzumab has been shown to induce their loss from the cell surface . When designing signaling experiments, include time-course measurements to capture both rapid and delayed signaling events, and consider the differential effects on various B cell subpopulations (naïve, memory, transitional). Pathway inhibitor studies can further elucidate the specific signaling cascades activated, providing insights into the mechanism of action that extends beyond simple target binding.

How should researchers design studies to assess CD22 antibody immunogenicity?

When assessing immunogenicity of CD22-targeted antibodies, researchers should implement a comprehensive testing protocol. For humanized antibodies like epratuzumab, measure human anti-human antibody (HAHA) responses rather than HAMA (human anti-mouse antibody) . The experimental protocol should include baseline samples before antibody administration and follow-up samples at multiple time points (14 days and approximately 2 months post-injection are typical minimal requirements) .

For the HAHA assay methodology:

• Coat microtitre plates (e.g., Maxisorp, Nunc) with 100 μl of a 5 μg/ml solution of the humanized antibody in 0.2 M sodium carbonate buffer (pH 9.6) and incubate at room temperature for 1 hour

• Block overnight with 250 μl 50 mM sodium phosphate buffer containing 5% BSA

• Wash four times with appropriate wash buffer

• Prepare serial dilutions of test serum and incubate 100 μl per well in duplicate at room temperature with gentle mixing

• After washing, add 100 μl goat anti-human Fc IgM or IgG conjugated to horseradish peroxidase at dilutions of 1/500 or 1/1000 respectively, and incubate for 1 hour

Include positive and negative controls to establish assay validity, and consider evaluating both IgM and IgG responses to capture different aspects of the immune response.

What pharmacodynamic markers should be monitored in CD22 antibody clinical trials?

For comprehensive pharmacodynamic monitoring of CD22 antibody therapy, researchers should track multiple parameters across different B cell subpopulations. Flow cytometry represents the gold standard approach, using antibody panels that include markers for B cell subsets (CD19, CD27, IgD, CD95) alongside CD22 expression monitoring . Key pharmacodynamic endpoints include:

• Changes in total B cell numbers and specific B cell subset distributions (naïve, memory, transitional B cells)

• CD22 expression levels on remaining B cells using non-competing anti-CD22 antibodies

• Changes in expression of functionally related surface molecules, particularly BCR-associated proteins

• Serum cytokine profiles reflecting B cell immunomodulation

In clinical trials of epratuzumab for SLE, researchers observed a 10-15% median decrease in CD22+ naïve B cells accompanied by a similar increase in CD22+ memory B cells, with continued decline in total B cells (50-60% reduction) after 9-12 months of treatment . Additionally, rapid reduction (~80%) of CD22 expression was observed within one week on all B cell subsets . These findings demonstrate the importance of monitoring multiple parameters over both short and long time periods to fully characterize pharmacodynamic effects.

How does the research approach differ when studying CD22 antibodies in autoimmune versus oncological conditions?

Researchers must adapt methodological approaches when studying CD22 antibodies across different disease contexts. In autoimmune conditions like systemic lupus erythematosus (SLE), the primary focus is on immunomodulation rather than cell depletion, with epratuzumab producing sustained improvements in disease activity through mechanisms that include modulation of B cell receptor proteins . Study endpoints should focus on disease activity scores, autoantibody levels, and immunological parameters reflecting B cell function rather than elimination.

In contrast, oncological applications often aim for direct cytotoxicity or enhanced immune targeting of malignant B cells. For B-cell malignancies like B-ALL and DLBCL, CD22 antibodies have demonstrated clinical efficacy , requiring outcome measures focused on cancer cell elimination, minimal residual disease assessment, and survival endpoints. When studying dual-targeting approaches (CD19/CD22), researchers must address the challenge of CD19 antigen loss as a mechanism of relapse .

The experimental approaches differ in several key aspects:

• Sample sources (peripheral blood in autoimmune conditions vs. bone marrow or lymph node in oncology)

• Cell population identification (focus on normal B cell subsets in autoimmune studies vs. malignant B cell identification in oncology)

• Functional assays (immunomodulation assessment vs. cytotoxicity/apoptosis induction)

In both contexts, understanding CD22 density and expression patterns remains essential, but the interpretation and application of these findings differ substantially based on therapeutic goals.

What characterization tests should be performed on clinical-grade CD22 antibodies?

Clinical-grade CD22 antibodies require comprehensive characterization through multiple analytical approaches. For purity assessment, researchers should employ analytical gel filtration using HPLC and SDS-PAGE, with acceptance criteria typically requiring >95% of the product to be in the intended antibody form . Immunoreactivity must be verified through competition ELISA with unmodified IgG conjugated to HRP, comparing binding characteristics to previously validated antibody batches .

Additionally, immunohistochemical analysis should be performed to confirm binding to target-expressing tissues with appropriate specificity and minimal cross-reactivity . For humanized antibodies, stability analysis using HPLC should be conducted on various timepoints from patient plasma samples . When characterizing novel antibodies like the recently developed 9A8 antibody against CD22, researchers should specifically assess sensitivity to low antigen density and evaluate tonic signaling characteristics .

The full characterization panel should include:

• Physical/chemical characterization (size, charge, glycosylation patterns)

• Functional binding assays (affinity measurements ideally using Biacore technology)

• Specificity testing across related and unrelated antigens

• Stability assessments under various storage and physiological conditions

• Batch consistency verification

How can researchers optimize antibody affinity measurements for CD22-targeting agents?

For precise affinity measurements of CD22-targeting antibodies, researchers should implement surface plasmon resonance (SPR) technology such as Biacore. When measuring epratuzumab binding to CD22, use Chinese hamster ovary-expressed CD22 extracellular domain as the target substrate . This approach has determined that epratuzumab binds to CD22-extracellular domain with a high affinity of KD = 0.7 nM , providing a benchmark for comparative studies.

When designing affinity measurement experiments:

• Include multiple antibody concentrations to establish accurate binding curves

• Implement proper controls including non-specific binding surfaces

• Conduct measurements under physiologically relevant conditions (pH, temperature, ionic strength)

• Compare novel antibodies to established standards like epratuzumab

• Consider epitope-specific factors, as CD22 has seven immunoglobular domains that may influence binding characteristics

To address the challenges of CD22's complex structure, researchers should supplement binding affinity data with functional assays that assess the consequences of binding, such as receptor internalization rates or downstream signaling events. This provides a more complete picture of antibody-target interactions beyond simple affinity measurements.

What are the key considerations for developing CD22 CAR-T cell therapies?

Developing effective CD22 CAR-T cell therapies requires addressing several unique challenges through systematic research approaches. The primary challenges include CD22's relatively low density (~2,839–3,470 molecules per cell) compared to other targets like CD19, and its large, rigid, heavily glycosylated ectodomain comprising seven immunoglobular domains, which can compromise immune synapse formation .

Researchers should focus on:

• Systematic testing of multiple distinct CD22 antibodies to identify optimal binding domains (data suggests the 9A8 antibody shows promising characteristics including sensitivity to low CD22 density and lack of tonic signaling)

• Evaluating CAR designs that accommodate the structural challenges of CD22's ectodomain

• Investigating optimal co-targeting strategies with CD19, as co-administration of separate CARs is costly while single CARs with dual specificity present technical challenges

• Developing pre-clinical models that accurately reflect the decrease in target density following initial CAR-T therapy, as CD22 expression can be further reduced after targeting

Research has shown that the correlation between affinity or membrane proximity of recognition epitope within Ig domains 3–6 of CD22 with CAR function is not straightforward , suggesting that empirical testing of multiple constructs remains essential. Researchers should systematically evaluate CAR designs through both in vitro functional assays and in vivo models that recapitulate the clinical challenges of target heterogeneity and antigen escape.

How does CD22 internalization affect antibody-drug conjugate (ADC) development strategies?

CD22's rapid internalization properties create both opportunities and challenges for antibody-drug conjugate (ADC) development that researchers must address through specialized experimental approaches. Studies show that binding of antibodies like epratuzumab to CD22 on B cell lines and primary B cells results in rapid internalization of the CD22/antibody complex . This internalization process is faster in cell lines at early time points compared to primary B cells, but reaches comparable maximum levels after several hours across all B cell populations .

For ADC development, researchers should:

• Characterize internalization kinetics across multiple timepoints (early time points are particularly important) and across different target cell populations

• Determine optimal antibody concentrations, as internalization appears to reach saturation at antibody concentrations of 1–5 μg/ml

• Evaluate different linker chemistries that align with the specific intracellular trafficking pathways of CD22

• Test various cytotoxic payloads with different mechanisms of action to identify those most effective following CD22-mediated internalization

• Develop assays to measure intracellular payload release and distribution following internalization

The significantly different internalization rates between cell lines and primary cells highlight the importance of using clinically relevant models in ADC development . Researchers should ultimately validate findings in patient-derived samples to ensure translational relevance of their ADC development programs.

What emerging technologies are advancing CD22 antibody research?

Recent technological advances are creating new opportunities for CD22 antibody research that investigators should consider incorporating into their experimental designs. Among the most promising approaches is the development of novel high-affinity antibodies against CD22, such as the 9A8 antibody, which demonstrates enhanced sensitivity to low CD22 density and favorable signaling properties . Dual-targeting approaches combining CD19 and CD22 recognition represent another significant advancement, though optimal implementation strategies remain under investigation .

For researchers planning future studies, key technological considerations include:

• Single-cell analysis techniques to better understand target heterogeneity across B cell malignancies and autoimmune conditions

• Advanced protein engineering approaches to address the structural challenges of CD22's ectodomain

• Novel animal models that better recapitulate human B cell biology and pathology

• Computational approaches to predict optimal epitope targeting and antibody designs

• Multiparametric assays that simultaneously assess binding, internalization, and functional outcomes